Indeed, positive immunostaining for pAKT, pERK, PTEN and EGFRvIII has been reported to predict sensitivity to EGFR tyrosine kinase inhibitors in non-small-cell lung cancer and glioblastoma (Han et al, 2004; Mellinghoff et al, 2005). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.